帕纳克斯人参:在阿尔茨海默氏症患者中是一种粉样蛋白,病理和认知功能的调节剂
Jaeuk Hwang1, Musung Keum2, Young Min Choe2,3
1Department of Psychiatry, Soonchunhyang University Hospital Seoul, Seoul, Republic of Korea.
Journal of ginseng research
|July 7, 2025
概括
帕纳克斯人参在阿尔茨海默病 (AD) 治疗方面表现有前途. 它的化合物可以减少粉样质斑块和陶,改善AD患者的认知功能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默氏症 (AD) 是痴呆的主要原因,由粉样斑块,病理和认知衰退标志着.
- 目前针对β-粉样蛋白 (Aβ) 的治疗方法存在局限性,需要对AD进行补充治疗.
- 帕纳克斯人参被认为具有认知益处,并具有AD干预的潜力.
研究的目的:
- 系统地审查帕纳克斯人参及其在阿尔茨海默氏症治疗中的治疗潜力.
- 探索P.人参对Aβ,陶蛋白和AD认知功能的影响.
- 总结前临床和临床证据,支持P.人参在AD治疗和预防中的作用.
主要方法:
- 对帕纳克斯人参和阿尔茨海默病的临床前和临床研究进行系统审查.
- 对神经保护机制的分析,包括Aβ生产抑制,Aβ清除增强和陶过酸化抑制.
- 在阿尔茨海默病模型和人类研究中评估认知结果.
主要成果:
- 帕纳克斯人参及其人参化物在阿尔茨海默病模型中显示出改善认知功能的潜力.
- 临床研究表明,在轻度认知障碍和主观记忆障碍方面,认知有好处.
- 用P.人参进行辅助疗法在阿兹海默病患者中显示出有前途,特别是那些没有阿波利波蛋白 ε4等位基因的患者.
结论:
- 潘纳克斯人参对阿尔茨海默病具有治疗和预防潜力.
- 神经保护机制涉及Aβ和tau病理的调制.
- 对P.人参化合物的进一步研究可以优化AD临床应用的疗效.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.4K
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
213
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
213
